Search results for " denosumab"

showing 5 items of 25 documents

Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology

2016

Introduction: Osteonecrosis of the jaw (ONJ) is a clinically important, potentially painful and debilitating condition, which can affect the quality of life of cancer patients. Since 2003, ONJ appeared as a Bisphosphonate(BP)-related class effect, and the term Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) was widespread. Areas Covered: Under discussion in this review is the fact that ONJ cases have been reported after treatment including antiangiogenic agents and other “targeted therapy”, with and without BPs. Consequently, the comprehensive term Medication-Related Osteonecrosis of the Jaw (MRONJ) has been introduced. The clinical aspects and the prognosis of ONJ associated with t…

aflibercept; bevacizumab; Bisphosphonate; Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ); denosumab; everolimus; Medication-Related Osteonecrosis of the Jaw (MRONJ); Osteonecrosis of the jaw (ONJ); sunitinib; temsirolimus; Angiogenesis Inhibitors; Antineoplastic Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Humans; Jaw Diseases; Molecular Targeted Therapy; Neoplasms; Osteonecrosis; Quality of Life; Risk Assessment; Pharmacology (medical)Oncologysunitinibmedicine.medical_treatmentAngiogenesis InhibitorstemsirolimuTargeted therapyAntineoplastic Agent0302 clinical medicineNeoplasmsPharmacology (medical)Molecular Targeted TherapyJaw DiseaseafliberceptOsteonecrosisGeneral MedicineDenosumab030220 oncology & carcinogenesisOsteonecrosiBisphosphonate-Associated Osteonecrosis of the JawAngiogenesis InhibitorHumanmedicine.drugmedicine.medical_specialtyBevacizumabAntineoplastic AgentsbevacizumabRisk AssessmentBisphosphonate-Related Osteonecrosis of the Jaw (BRONJ)Medication-Related Osteonecrosis of the Jaw (MRONJ)03 medical and health sciencesInternal medicinemedicineBisphosphonateHumansBisphosphonate-associated osteonecrosis of the jawbusiness.industryeverolimuCancerdenosumab030206 dentistryBisphosphonatemedicine.diseaseOsteonecrosis of the jaw (ONJ)Quality of LifeNeoplasmJaw DiseasesOsteonecrosis of the jawbusinessJaw DiseasesExpert Opinion on Drug Safety
researchProduct

Medication-Related Osteonecrosis of Jaws (MRONJ) Prevention and Diagnosis: Italian Consensus Update 2020

2020

The Medication-Related Osteonecrosis of Jaws (MRONJ) diagnosis process and its prevention play a role of great and rising importance, not only on the Quality of Life (QoL) of patients, but also on the decision-making process by the majority of dentists and oral surgeons involved in MRONJ prevention (primary and secondary). The present paper reports the update of the conclusions from the Consensus Conference—held at the Symposium of the Italian Society of Oral Pathology and Medicine (SIPMO) (20 October 2018, Ancona, Italy)—after the newest recommendations (2020) on MRONJ were published by two scientific societies (Italian Societies of Maxillofacial Surgery and Oral Pathology and Medicine, SI…

bisphosphonateOral SurgeonHealth Toxicology and Mutagenesislcsh:MedicineMRONJantiangiogenic agents; antiresorptive drugs; bisphosphonates; cancer; denosumab; dentistry; MRONJ; oral surgery; osteoporosis; prevention models; bisphosphonate-associated osteonecrosis of the jaw; bone density conservation agents; diphosphonates; humans; Italy; quality of life0302 clinical medicineprevention modelCancerantiangiogenic agentsdentistryBone Density Conservation AgentsDiphosphonatesConference ReportBisphosphonatesAntiresorptive DrugsDenosumabItaly030220 oncology & carcinogenesisBisphosphonate-Associated Osteonecrosis of the JawDenosumabmedicine.drugoral surgerymedicine.medical_specialtyOral surgery03 medical and health sciencesOral surgeryAntiangiogenic agentsOral and maxillofacial pathologymedicinecancerHumansantiangiogenic agentantiresorptive drugsIntensive care medicinePrevention modelsbisphosphonatesantiresorptive drugAntiangiogenic agentsbusiness.industrylcsh:RPublic Health Environmental and Occupational Healthdenosumab030206 dentistrymedicine.diseaseosteoporosisAntiresorptive drugsDentistryOsteoporosisprevention modelsbusinessAntiangiogenic agents; Antiresorptive drugs; Bisphosphonates; Cancer; Denosumab; Dentistry; MRONJ; Oral surgery; Osteoporosis; Prevention models
researchProduct

Diabetes Mellitus and Its Association to the Occurrence of Medication-Related Osteonecrosis of the Jaw

2016

To date there is no consensus on the role of diabetes in the development of medication-related osteonecrosis of the jaws (MR-ONJ). Therefore, this study aimed to investigate the prevalence of diabetes and pathological glucose metabolism in patients with MR-ONJ compared to the general population. All maxillofacial surgery inpatients in one year at our department were investigated regarding diagnosis, anamnesis, medication, and blood glucose readings. 1374 records were analyzed. 35 patients with MR-ONJ were identified. Diabetics accounted for 14.3%. No significant difference in the prevalence of known diabetes was found, except for pathological glucose metabolism in patients with MR-ONJ (p &l…

medicine.medical_specialtyPopulationArticle03 medical and health sciences0302 clinical medicineInternal medicineDiabetes mellitusmedicinediabetes; hyperglycemia; bisphosphonates; denosumab; MR-ONJ; BP-ONJRisk factoreducationGeneral DentistryPathologicalbisphosphonatesAnamnesiseducation.field_of_studyBP-ONJdiabetesbusiness.industrySignificant differencedenosumab030206 dentistrymedicine.diseaseSurgerylcsh:RK1-715Denosumab030220 oncology & carcinogenesislcsh:DentistryMR-ONJhyperglycemiaOsteonecrosis of the jawbusinessmedicine.drugDentistry Journal; Volume 4; Issue 2; Pages: 17
researchProduct

A pragmatic window of opportunity to minimise the risk of MRONJ development in individuals with osteoporosis on Denosumab therapy: a hypothesis

2021

Abstract Denosumab is associated with the development of medication-related osteonecrosis of the jaw (MRONJ), an uncommon but severe oral side effect with a higher prevalence in metastatic cancer patients than in patients with metabolic bone fragility. Although several oral triggers can initiate MRONJ, invasive oral treatments and tooth extraction still remain the most common precipitating event. In general, tooth extraction and oral surgery should be avoided in patients at increased risk of MRONJ, while extraction of non-restorable teeth should be performed based on specific risk reduction protocols to eliminate dental/periodontal infections, still protecting from MRONJ onset. Based on th…

medicine.medical_specialtySide effectOsteoporosisSpecialties of internal medicine030209 endocrinology & metabolismMRONJOral surgery tooth extraction03 medical and health sciences0302 clinical medicineOral surgeryMedication-related osteonecrosis of the jawmedicineDenosumab osteoporosis; Medication-related osteonecrosis of the jaw; MRONJ; Oral surgery tooth extraction; Denosumab; Diphosphonates; Humans; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; OsteoporosisHumansIntensive care medicineGeneral Dentistrytooth extractionBisphosphonate-associated osteonecrosis of the jawDiphosphonatesBone Density Conservation Agentsbusiness.industryHypothesismedicine.diseaseosteoporosisDenosumab osteoporosisBone Density Conservation Agentsstomatognathic diseasesDenosumabOtorhinolaryngologyRC581-951030220 oncology & carcinogenesisDental surgeryOral and maxillofacial surgeryBisphosphonate-Associated Osteonecrosis of the JawNeurology (clinical)DenosumabbusinessOsteonecrosis of the jawmedicine.drugHead & Face Medicine
researchProduct

Onset of MRONJ in Breast Cancer Patients after Switching from Low to High Dose of Bone Modifying Agents Due to Bone Metastases Development: A Single …

2022

Background: Medication-Related Osteonecrosis of the Jaw (MRONJ) is an adverse drug reaction mainly associated to bone modifying agents (BMAs). Breast cancer (BC) is the most frequent cancer worldwide. Its therapy can cause cancer treatment-induced bone loss (CTIBL), commonly treated with BMAs. The aims of this retrospective study are: to describe characteristics of BC patients under BMAs for CTIBL; to record any switch to high-dose BMAs; to assess MRONJ onset and to identify any factors associated with it. Patients: Authors included patients referred for MRONJ prevention to the Unit of Oral Medicine (University Hospital of Palermo). Results: Fourteen female BC patients under low-dose BMAs f…

osteonecrosis of the jawbisphosphonatebreast cancerBPosteonecrosis of the jaw; MRONJ; cancer treatment-induced bone loss; CTIBL; breast cancer; osteoporosis; bone metastases; bisphosphonates; BPs; denosumabcancer treatment-induced bone loosteoporosidenosumabPharmacology (medical)MRONJCTIBLbone metastaseOral; Volume 2; Issue 4; Pages: 274-285
researchProduct